02142

Stock Performance: HBM HOLDINGS-B (02142.HK) experienced a decline of 3.849%, with a short selling amount of $12.54 million and a ratio of 21.210%.

Strategic Collaboration: HBM HOLDINGS-B has entered a multi-year global collaboration with Bristol Myers Squibb to develop next-generation multi-specific antibodies.

Financial Terms: The agreement could yield HBM HOLDINGS-B up to $90 million in initial payments, with potential development and commercial milestones totaling up to $1.035 billion.

Royalty Structure: HBM HOLDINGS-B may also receive tiered royalties if Bristol Myers Squibb decides to advance all potential programs under the collaboration.

Share Placement Announcement: HBM Holdings-B plans to place 45.022 million new shares, representing approximately 5.17% of its enlarged issued share capital, at a price of $11.5 per share.

Discount on Share Price: The placement price reflects a discount of about 9.45% compared to the closing price of $12.7 per share on August 28.

Use of Proceeds: The company expects to raise around $512 million, with funds allocated for research and development (50%), clinical trials of existing drugs (40%), and general corporate purposes (10%).

Market Activity: As of the latest data, short selling amounted to $24.46 million with a ratio of 15.061%.